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ABBREVIATION
ICD-9-CM International Classification of
Diseases, Ninth Revision,
Clinical Modification
AIM To examine the longitudinal trends of cardiometabolic diseases in a large sample of
adults with cerebral palsy (CP).
METHOD The Optum Clinformatics Data Mart is a de-identified nationwide claims database of
beneficiaries from a single private payer. Beneficiaries were included if they had an
International Classification of Diseases, Ninth Revision, Clinical Modification code for a
diagnosis of CP. Adults with at least 3 years of continuous enrollment on a single plan
between 2002 and 2009 were included in the final analyses (n=2659). We examined the
longitudinal trends of incident diabetes mellitus, hypercholesterolemia, hypertension, cardiac
dysrhythmias, and atherosclerosis, stratified by age categories: 18 to 39 years, 40 to 59 years,
and 60 years and over. Kaplan–Meier product-limit survival curves were compared across age
categories for each of the cardiometabolic outcomes, and a Cox proportional hazards
regression was run to determine adjusted hazard ratios.
RESULTS The cumulative incidence of each of the cardiometabolic diseases ranged from 6.0%
for atherosclerosis to 34.4% for hypercholesterolemia at 3 years and over. Risk-adjusted Cox
proportional hazard models revealed that age was a robust predictor of survival for each
outcome, with higher hazard ratio ranges in middle age (hazard ratio 1.41–2.72) and older
adults (hazard ratio 2.20–5.93) compared with young adults.
INTERPRETATION Adults with CP have high rates of cardiometabolic diseases; and disease-
free survival shortens significantly with higher ages.
Cerebral palsy (CP) is the most common pediatric-onset
physical disability, with an estimated prevalence ranging
from 2.6 to 3.1 cases per 1000 live births in the USA.1
Many individuals with mild to moderate CP can expect
near-normal life expectancies,2 yet there is a lack of clinical
follow-up for patients after they transition from pediatric
to adult primary care, and insufficient cohort data to track
patients with CP longitudinally.3 The vast majority of clin-
ical research has come from small single-center interven-
tions, and is centrally focused on symptom management
for children or adolescents with CP.
Despite the shortage of research to track lifelong health
and chronic disease trajectories in this population, there is
ample evidence demonstrating that individuals with CP
have significant and progressive motor impairment,
unhealthy body composition, and excessive sedentary
behavior profiles, all of which increase with age.4–6 These
factors place adults with CP at a heightened risk for sec-
ondary chronic conditions7 that further worsen functional
status and quality of life, as well as leading to decreased
independence.8 Indeed, CP represents a significant lifetime
disability for individuals, their families, and caregivers, and
is associated with increased prevalent cardiometabolic dis-
eases,9 chronic multimorbidity,10 and a shortened life
expectancy.11 However, what remains to be determined are
the age-related trajectories of cardiometabolic diseases
among adults with CP. The objectives of this study were
therefore to build upon previous findings by analyzing lon-
gitudinal trends and disease-free survival of car-
diometabolic diseases (e.g. diabetes, hypertension,
atherosclerosis) among adult beneficiaries with CP within a
managed-care network of enrollees throughout the USA.
METHOD
Data source
The Clinformatics Data Mart Database (OptumInsight,
Eden Prairie, MN, USA), is a de-identified nationwide
claims database of all beneficiaries from a single private
payer. These data comprise all enrollees who had medical
and pharmacy insurance coverage at any time between 1st
January 2001 and 31st December 2014; a total of
58 800 802 unique patients. Data are organized by a speci-
fic patient identification number, which ensures longitudi-
nal follow-up even if there were changes in plan details or
484 DOI: 10.1111/dmcn.13777 © 2018 Mac Keith Press
gaps in insurance coverage, as previously described.12 The
data set includes information on medical claims for all con-
ditions for the enrollees as well as demographic informa-
tion. This database has been previously used to investigate
other conditions and their complications, including other
neurological,12 urological,13 and metabolic14 conditions.
Since the data were de-identified, the University of Michi-
gan Institutional Review Board approved this as a non-
regulated study.
Sample selection
We obtained access to data for all enrollees with CP, aged
at least 18 years, during the period from 2001 to 2014.
Enrollees were included in the data set if they had an
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) code for a CP diagno-
sis (ICD-9-CM codes 343 and 333.71) (all ICD-9 codes
are provided in Table I). Individuals with pre-existing car-
diometabolic disease (at least one diagnosis of car-
diometabolic disease in the 3mo preceding the index
diagnosis of CP) were excluded, as were those with non-
continuous enrollment, and those younger than 18 years of
age at the time of index CP diagnosis. Enrollees with at
least 3 years of continuous enrollment on a single plan
from the index diagnosis of CP, between 2002 and 2009,
were included in the final analyses (n=2659). A sensitivity
analysis was conducted for two reasons: (1) we evaluated the
sample size at 3 months, 6 months, and 12 months before
the index diagnosis for continuous enrollment and propor-
tion with previous disease diagnoses; and (2) we evaluated 3
years, 4 years, and 5 years of continuous enrollment on a
single plan for follow-up post-index CP diagnosis to deter-
mine the appropriate sample for final analysis.
Covariates
Enrollee information included as covariates was limited to
the available socio-demographic data provided in the
insurance claim. Enrollee demographic information for sex,
ethnic group (white, black, Latino, Asian, other), education
level (less than high school, high school diploma, some
college, college diploma, or advanced degree), and house-
hold net worth (0 to <US$40 000, US$40000 to <US$50
000, US$50 000 to <US$60 000, US$60 000 to <US$75
000 to <US$100 000, or ≥US$100 000) were included.
Age was categorized as young (18–<40y), middle-aged (40–
<60y), and older (≥60y) adults.
Outcomes
The study outcomes were diagnoses of any of the follow-
ing five cardiometabolic diseases/conditions, using ICD-9-
CM codes (all ICD-9 codes are provided in Table I), after
the CP diagnosis/index date: (1) diabetes mellitus, (2)
hypercholesterolemia, (3) hypertension, (4) cardiac dys-
rhythmias, and (5) atherosclerosis. These conditions were
selected in accordance with guidance from the literature
pertaining to cardiometabolic diseases in adults and adults
with disabilities,15,16 and availability of the diagnosis within
the claims data.
Statistical analysis
All analyses were performed using SAS version 9.4 (SAS
Institute, Cary, NC, USA). Enrollee characteristics were
summarized using means (standard deviations [SDs]) for
continuous variables, and frequencies and percentages for
categorical variables. Bivariate analysis was conducted
using v2 tests or Fisher’s exact test in the case of small
sample size for categorical variables, or an analysis of vari-
ance or non-parametric tests for continuous variables. The
analysis of variance assumptions required us to check con-
tinuous variables based on quantile–quantile plots, assess-
ing degrees of skew and kurtosis, and evaluating whether
normally distributed errors were evident. We also reviewed
the histogram of the distribution for visual inspection for
any strong departures from normality. Event-free survival
was estimated for young, middle-aged, and older adults
using the Kaplan–Meier product-limit survival curves for
at least 3 years of follow-up. Cumulative incidence was
determined as 1 minus the survival probability. Cox pro-
portional hazards regression was used to estimate adjusted
hazard ratios with the dependent variable as the time to
first occurrence for each of the six cardiometabolic out-
comes. Proportional hazards assumption was assessed using
log-rank tests and evaluation of the Kaplan–Meier pro-
duct-limit survival curves. Adjusted failure rates were esti-
mated using the Cox model. Patients were right censored
at the date they discontinued enrollment or at the end of
the follow-up period in the database (i.e. 31st December
2014). We conducted a sensitivity analysis by fitting Cox
Table I: International Classification of Diseases, Ninth Revision (ICD-9)









Other specified infantile CP 343.8








aOther CP include mixed CP and spastic monoplegia.
What this paper adds
• Adults with cerebral palsy have high rates of cardiometabolic diseases.
• Disease-free survival of all cardiometabolic diseases shortens significantly
with higher ages.
• The highest rates were for hypercholesterolemia and hypertension.
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regression models without household income to examine
whether the significance of adjusted hazard ratios changed
as a result of its omission from our final models. For each
cardiometabolic outcome, we determined that household
income did not change overall significance; therefore, it
seems final model estimates were sufficiently unbiased and
determined income was an important socio-demographic
covariate to include in the adjustment. A two-tailed p value
of <0.05 was used as the threshold for statistical signifi-
cance in all tests.
RESULTS
A total of 2659 adults with CP met the inclusion criteria.
The mean time in the plan for eligible enrollees was
7 years plus or minus 2 years 10 months, ranging from
3 years (inclusion criterion) to 11 years (maximum avail-
able data from 2001–2011). The sample included 1285
females (48%); among those with known ethnic group,
there were 1996 whites (75.0%), 256 blacks (9.6%), 204
Hispanics (7.7%), and 59 Asians (2.2%). Of the 2659, 735
enrollees (27.6%) came from a household with incomes of
more than US$100,000, and 454 enrollees (17.1%) had a
college diploma or higher education level (presented in
Table II).
The cumulative incidence of each of the cardiometabolic
diseases in all enrollees ranged from 6.0% to 34.4% at
3 years and over, and was 11.6% for diabetes mellitus,
34.4% for hypercholesterolemia, 28.9% for hypertension,
13.2% for cardiac dysrhythmias, and 6.0% for atheroscle-
rosis.
Kaplan–Meier curves for the unadjusted disease-free sur-
vival for each of the cardiometabolic outcomes in young,
middle-aged, and older adults are shown in Figure 1. Mean
disease-free survival rates varied greatly between outcomes
and were generally significantly less for middle-aged and
older adults compared with young adults. Specifically, dis-
ease-free survival (meanstandard errors) was 1728.5 plus-
minus 14.4 days, 1629.5 plus or minus 18.9 days, and
1472.9 plus or minus 33.6 days for diabetes mellitus;
1487.5 plus or minus 21.5 days, 1165.7 plus or minus
26.2 days, and 943.0 plus or minus 34.4 days for hyperc-
holesterolemia; 1553.2 plus or minus 20.7 days, 1243.2
plus or minus 26.6 days, and 960.3 plus or minus 36.6 days
for hypertension; 1645.3 plus or minus 17.8 days, 1568.0
plus or minus 20.6 days, and 1452.1 plus or minus
33.0 days for cardiac dysrhythmias; and 1507.0 plus or
minus 5.2 days, 1736.2 plus or minus 11.0 days, and
1623.7 plus or minus 22.3 days for atherosclerosis among
young, middle-aged, and older adults with CP respectively.
Fully adjusted multivariable survival analyzes demon-
strated a significant effect of higher hazard ratios in middle
age (hazard ratio 1.41–2.72) and older adults (hazard ratio
2.20–5.93) compared with young adults. Further, risk-
adjusted Cox proportional hazard models revealed that sex
and ethnic group were also associated with various inci-
dent outcomes (Tables SI–SV, online supporting informa-
tion).
DISCUSSION
We calculated the longitudinal trends and disease-free sur-
vival of cardiometabolic diseases and risk factors in a large
sample of adults with CP. The principal findings were that
adults with CP have high rates of incident cardiometabolic
diseases; and that disease-free survival shortens significantly
with higher age stratification. Specifically, we determined
that the cumulative incidences (≥3y) of type 2 diabetes,
hypercholesterolemia, hypertension, cardiac dysrhythmias,
and atherosclerosis were between 6% and 34% in adults
with CP within a nationwide claims database. The highest
rates observed were for hypercholesterolemia and hyper-
tension, at 34.4% and 28.9% respectively, which are simi-
lar to the lifetime risk of these outcomes in the otherwise
healthy, general population without CP.17 It is plausible
that the lower rates observed for atherosclerosis may be
due in part to the irregularity of clinical cardiovascular
screening in the population with CP. Indeed, there is a
well-established literature describing the disparities in
healthcare access and use among persons with intellectual
and physical disabilities,18 and particularly affecting pre-
ventive health services use and screening rates. With the
relatively high incidence for atherosclerosis risk factors
described in this study (i.e. hypercholesterolemia), and the
additional risk factors related to obesity and decreased
physical activity noted elsewhere,19,20 the true rate for
undetected atherosclerosis in CP is likely much higher.
This may also reflect a selection bias towards higher-func-
tioning individuals with CP and an underrepresentation of
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Less than high school 0.5 0.4
High school diploma 24.8 28.7
Some college 53.8 53.4
College 18.6 15.7
Advanced degree
Household annual income, %
Unknown/missing 27.7 27.1
<US$40 000 15.5 12.3
US$40 000–49 999 5.9 6.2
US$50 000–59 999 5.5 6.5
US$60 000–74 999 7.7 8.7
US$75 000–99 999 11.1 10.6
>US$100 000 26.6 28.6
aContinuous variables expressed as medians with 25th and 75th
centiles.
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overall cardiometabolic disease burden, as it is plausible
that many individuals with more severe physical and intel-
lectual disabilities or complex diagnoses may be using
social healthcare coverage. With the emergence of and
improvements in novel and non-invasive methods of
screening for subclinical atherosclerotic plaques (e.g. high-
resolution ultrasound can provide images of the arterial
wall and plaques at a resolution of 0.2mm,21 as well as
intima-media thickness),19 future efforts to encourage
adoptions of these measurements as a feature of standard
clinical care for individuals with CP are certainly
warranted.
Nevertheless, these findings raise critical questions
about preventable cardiometabolic health complications in
CP through the lifespan. We and others have proposed a
rationale for development of registries to better under-
stand and prevent age-related chronic disease risk in the
CP population;5,8,22 however, this is the first study to
examine the longitudinal trends and disease-free survival
of primary cardiometabolic diseases among adults with
CP. Based on these findings and those of other recent
reports showing increased risk of prevalent chronic car-
diometabolic conditions and other non-communicable dis-
eases among adults with CP,19,20,23 future efforts are
needed not only to better understand the healthcare bur-
den associated with these conditions in CP, but, more
importantly, to facilitate the development of appropriate
clinical screening algorithms and design of early behav-
ioral interventions to reduce risk of disease onset/progres-
sion in this population.
Among individuals with CP, many more deaths are
attributed to diseases of the circulatory and respiratory sys-
tems compared with the general population.24 A recent
analysis indicated that the mortality rate of orally fed
adults with CP has increased over the past 30 years, in
contrast to a decline in mortality rates of the general popu-
lation.25 The factors contributing to this trend have not
been thoroughly investigated; however, records reveal that
mortality caused by ischemic heart disease and cancer is
higher among adults with CP,24 as is the risk for incident
stroke.26 There is substantial evidence that individuals with
CP have lower cardiovascular fitness, less muscle mass,
increased inter- and intramuscular fat deposition, dimin-
ished bone density and increased marrow adiposity, and
reduced functional reserve throughout childhood and into
adulthood.4–6,27–29 These factors place individuals with CP
at a heightened risk for secondary health concerns such as
accelerated functional losses, early sarcopenia, and obesity-
related cardiometabolic diseases.9,22 Yet, despite the
overwhelming attention and evidence about function and
participation changes among individuals with CP through-
out the lifespan, there has been a complete paucity of
information about longitudinal changes to cardiometabolic
health status in this population. McPhee et al. recently
demonstrated that age was significantly associated with
decreased endothelial function and arterial stiffness in CP,


























































































365 730 1095 182514600
Follow-up time (days)
365 730 1095 182514600
Follow-up time (days)
365 730 1095 182514600
Follow-up time (days)












Figure 1: Disease-free survival for young, middle-aged, and older adults
and Kaplan–Meier product-limit survival curves, for (a) type 2 diabetes, (b)
hypercholesterolemia, (c) hypertension, (d) cardiac dysrhythmias, and (e)
atherosclerosis. [Colour figure can be viewed at wileyonlinelibrary.com].
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Their findings support those of ours and others, which
indicate that adults with CP have an elevated risk of many
cardiometabolic conditions.9,20 We have also recently
demonstrated that the prevalence of multimorbidity among
middle-aged adults with CP (40–60y) was nearly 60%,15
which is similar to older adults without CP.
This evidence collectively lends strong support for the
need to approach healthcare delivery for persons with CP
within the context of a life-course health development
model.30 Indeed, chronic health is a set of capacities that
evolve over a lifetime and allow or prevent individuals to
interact within their environments and achieve well-being.
The framework that encompasses clinical care for patients
with CP has been largely confined to issues that arise
during childhood and adolescence, with little to no focus
on understanding life-course health development. Our
findings demonstrate that age is a robust risk factor for
incident type 2 diabetes, hypercholesterolemia, hyperten-
sion, cardiac dysrhythmias, and atherosclerosis among
adults with CP. These five conditions represent the pri-
mary risk factors for several leading causes of death in
the USA (i.e. diabetes, heart disease, and stroke), yet
there are various other important age-related health out-
comes that have yet to receive adequate attention in the
CP population. Thus, future research is needed to better
describe the pattern of age-related trajectories for other
common, non-communicable diseases in CP, such as can-
cer, Alzheimer disease, depression and other psychiatric
disorders, osteoporosis, frailty, etc. Regardless, given the
interrelationships between age-related declines in physical
and cognitive function, muscle atrophy, and risk for obe-
sity, there is a dire need for early behavioral interventions
in this population with a priority focus on supporting
lifelong physical activity participation and healthy nutri-
tional habits.
Strengths/limitations
As with all cohort studies, there are several important limi-
tations to this study. First, we did not include a compar-
ison group for cumulative incidence estimates, as this was
not the primary aim of the study. However, a formal statis-
tical comparison with a propensity-matched cohort of typi-
cally developed adults would provide subsequent support
for altered risk patterns in this population. Second, we can-
not rule out time-varying confounding since baseline mea-
surements of all covariates were included in our final
models. We were unable to determine whether other com-
peting risks or unmeasured confounding (i.e. other risk fac-
tors [e.g. smoking], protective factors [e.g. physical
activity], or existing diseases [e.g. cancer]) may have influ-
enced the observed survival trajectories. Third, as with any
long-term prospective study, losses to follow-up may have
resulted in an underestimation of the true association if
individuals who were sicker or more impaired were more
likely to drop out. Lastly, our sample included adults with
CP from a nationwide claims database of all beneficiaries
from a single private payer. Therefore, our lack of an asso-
ciation between low socio-economic status indices with
incident cardiometabolic outcomes may have been caused
by an underrepresentation of adults with CP having lower
socio-economic status. Future studies are certainly needed
to examine the extent to which disparities exist across fed-
eral healthcare-covered versus privately insured individuals
with CP. Despite these limitations, this study has various
strengths. Most notably, this is the first study to examine
changes in primary cardiometabolic health outcomes in a
large, nationally representative sample of adults in the
USA with CP. This is particularly important since adults
with CP represent a growing population with unique and
poorly understood clinical and preventive healthcare needs.
CONCLUSIONS
The cumulative incidence (≥3y) of cardiometabolic dis-
eases in adults with CP ranged from 6.0% to 34.4%, and
was 11.6% for diabetes mellitus, 34.4% for hypercholes-
terolemia, 28.9% for hypertension, 13.2% for cardiac dys-
rhythmias, and 6.0% for atherosclerosis. Risk-adjusted
Cox proportional hazard models revealed that age was a
robust predictor of survival for each outcome, with higher
hazard ratio ranges in middle age (hazard ratio 1.41–2.72)
and older adults (hazard ratio 2.20–5.93) compared with
young adults. Therefore, adults with CP have high rates
of incident cardiometabolic diseases; and disease-free sur-
vival shortens significantly with higher age. On the basis
of these findings, future efforts are needed not only to
better understand the healthcare burden associated with
these conditions in CP, but more importantly to facilitate
the development of appropriate clinical screening algo-
rithms and design of early behavioral interventions to
reduce risk of disease onset/progression in this high-risk
population.
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RESUMEN
TENDENCIAS RELACIONADAS CON LA EDAD EN LA ENFERMEDAD CARDIO-METABOLICA EN ADULTOS CON PARALISIS CEREBRAL
OBJETIVO Examinar las tendencias longitudinales de las enfermedades cardio-metabolicas en una gran muestra de adultos con
paralisis cerebral (PC).
METODO El Data Mart de Optum Clinformatics es una base de datos de reclamaciones nacional anonima de beneficiarios de un
unico proveedor de servicios de salud privado. Se incluyeron los beneficiarios si tenıan un Codigo de Clasificacion Internacional
de Enfermedades, Novena Revision, Modificacion Clınica para un diagnostico de PC. Los adultos con al menos 3 a~nos de
inscripcion continua en un solo plan entre 2002 y 2009 se incluyeron en los analisis finales (n=2659). Examinamos las tendencias
longitudinales de diabetes mellitus incidente, hipercolesterolemia, hipertension, disritmias cardıacas y aterosclerosis, estratificadas
por categorıas de edad: de 18 a 39 a~nos, de 40 a 59 a~nos y mayores de 60 a~nos. Se compararon las curvas de supervivencia del
lımite de producto de Kaplan-Meier para cada categorıa de edad para cada resultado cardio-metabolico, y se realizo una regresion
de riesgos proporcionales de Cox para determinar los cocientes de riesgo ajustados.
RESULTADOS La incidencia acumulada de cada una de las enfermedades cardio-metabolicas vario del 6.0% para la aterosclerosis
al 34.4% para la hipercolesterolemia a los 3 a~nos y mas. Los modelos de riesgo proporcional de Cox ajustados por riesgo
revelaron que la edad era un predictor robusto de supervivencia para cada resultado, con rangos de razon de riesgo mas altos en
la mediana edad (razon de riesgo 1.41–2.72) y adultos mayores (razon de riesgo 2.20–5.93) en comparacion con los adultos
jovenes.
INTERPRETACION Los adultos con PC tienen altas tasas de enfermedades cardio-metabolicas; y la supervivencia libre de
enfermedad se acorta significativamente con las edades mas altas.
RESUMO
TENDÊNCIAS RELACIONADAS A IDADE EM DOENCA CARDIO-METABOLICA ENTRE ADULTOS COM PARALISIA CEREBRAL
OBJETIVO Examinar as tendências longitudinais de doencas cardio-metabolicas em uma grande amostra de adultos com paralisia
cerebral (PC).
METODO O Optum ClinformaticsTM Data Mart e uma base de dados nacional n~ao-identificada de beneficiarios de um convênio
privado. Os beneficiarios foram incluıdos se tivessem uma Classificac~ao internacional de doencas, nona revis~ao, codico de
modificac~ao clınica para diagnostico de PC. Adultos com pelo menos 3 anos de envolvimento contınuo em um unico plano entre
2002 e 2009 foram incluıdos na analise final (n=2659). Examinamos as tendências longitudinais de incidência de diabetes mellitus,
hipercolesterolemia, hipertens~ao, disritmias cardıacas e aterosclerose, estratificadas por categorias etarias: 18 a 39 anos, 40 a 59
anos, e acima de 60 anos. Curvas de sobreviência produto-limite de Kaplan–Meier foram comparadas entre categorias etarias para
cada uma das condic~oes cardio-metabolicas, e uma regress~ao de riscos proporcionais de Cox foi realizada para determinar as
taxas ajustadas de risco.
RESULTADOS A incidência cumulativa de cada doenca cardio-metabolica variou de 6.0% para aterosclerose a 34.4% para
hipercolesterolemia em 3 anos ou mais. Os modelos de risco proporcionais de Cox ajustados revelaram que a idade foi um
preditor robusto da sobrevivência para cada desfecho, com maior taxa de risco na meia idade (taxa de risco 1.41–2.72) e em
adultos mais velhos (taxa de risco 2.20–5.93) em comparac~ao com jovens adultos.
INTERPRETAC~AO Adultos com PC tem taxas altas de doencas cardio-metabolicas; a sobrevivência sem doencas se reduz
significantemente em maiores idades.
